People at High Risk of Influenza Complications and Therefore Recommended for Antiviral Treatment of Suspected or Confirmed Influenza

Children aged <2 years
Adults aged ≥65 years
Persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematologic (including sickle cell disease), or metabolic disorders (including diabetes mellitus) or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
Persons with immunosuppression, including that caused by medications or by HIV infection
Women who are pregnant or postpartum (within 2 weeks after delivery)
Persons aged <19 y who are receiving long-term aspirin therapy
American Indian/Alaska Native persons
Residents of nursing homes and other chronic care facilities
  • Adapted from the CDC. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(RR-1):1–24.